Table 2.
The relationship between clinical outcomes and AGR
| AGR | Prevalence (%) | Crude OR (95% CI) | Adjusted OR (95% CI) |
|---|---|---|---|
| Clinical remission | |||
| Low AGR | 25/67 (37.3) | 1.00 | 1.00 |
| Moderate AGR | 38/70 (54.3) | 2.00 (1.01–3.98) | 2.62 (1.22–5.76) |
| High AGR | 49/68 (72.1) | 4.33 (2.13–9.11) | 5.85 (2.52–14.18) |
| Very high AGR | 45/68 (66.2) | 3.29 (1.64–6.75) | 4.97 (2.14–12.04) |
| P for trend | 0.19 | ||
| Complete MH | |||
| Low AGR | 9/67 (13.4) | 1.00 | 1.00 |
| Moderate AGR | 16/70 (22.9) | 1.91 (0.79–4.85) | 2.36 (0.92–6.44) |
| High AGR | 23/68 (33.8) | 3.29 (1.43–8.16) | 4.03 (1.56–11.51) |
| Very high AGR | 24/68 (35.3) | 3.52 (1.53–8.69) | 5.22 (1.97–14.89) |
| P for trend | 0.001 | ||
| MH | |||
| Low AGR | 36/67 (53.7) | 1.00 | 1.00 |
| Moderate AGR | 41/70 (58.6) | 1.22 (0.62–2.40) | 1.05 (0.50–2.20) |
| High AGR | 47/68 (69.1) | 1.93 (0.96–3.93) | 1.43 (0.64–3.21) |
| Very high AGR | 48/68 (70.6) | 2.07 (1.02–4.25) | 1.62 (0.71–3.74) |
| P for trend | 0.19 |
AGR, albumin to globulin ratio; OR, odds ratio; CI, confidence interval; MH, mucosal healing.
Adjusted for age, sex, use of prednisolone, body mass index, onset age, use of tumor necrosis factor-α monoclonal antibody, and disease extent.